Alzheimer's drug candidate no better than placebo in study

09/16/2008 | Bloomberg

A 12-week study found that AZD3480, an investigational drug from AstraZeneca and Targacept, was just as effective as placebo or standard treatment Aricept in improving cognition in Alzheimer's disease patients. The finding was "affected by the fact that the placebo group showed unexpected improvement over the treatment time, rather than the expected decline," Targacept President and CEO J. Donald deBethizy said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Teaching Associate (Hospitality Management)
University of Illinois at Urbana-Champaign
Urbana, IL
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA